Last reviewed · How we verify
NCT05136924
IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL
Phase 2 trial testing OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo in Dry Eye Disease in 20 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Vance Thompson Vision - MT |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 December 2021 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo — full drug profile →
- Placebo (vehicle) nasal spray
Conditions studied
- Dry Eye Disease — all drugs for Dry Eye Disease →
Sponsor
Vance Thompson Vision - MT — full company profile →
Who can join
18 and older, any sex, with Dry Eye Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated study to Assess the Efficacy of OC-01 (varenicline) Nasal Spray on signs and symptoms of Dry Eye Disease in subjects following Corneal Collagen Crosslinking (CXL)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Varenicline Nasal Spray for the Treatment of Dry Eye Disease Following Corneal Collagen Crosslinking.
Ferguson TJ, Durgan D, Whitt T, Swan RJ. · · 2025 · PMID 40088395 · DOI 10.1007/s40123-025-01118-x
Verify or expand the search:
- PubMed search for NCT05136924
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye Disease
Currently open trials in the same condition.
- NCT06596733 — Vit-A-Vision® Clinical Investigation · NA · recruiting
- NCT07264517 — Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). · Phase 2 · recruiting
- NCT07025811 — A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment · Phase 4 · recruiting
- NCT04946721 — 2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD · recruiting
- NCT06696625 — Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye · NA · recruiting
Other Vance Thompson Vision - MT trials
Trials by the same sponsor.
- NCT04549935 — The PRIME Study: A Randomized, Controlled, Prospective Study · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05136924 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vance Thompson Vision - MT
- Last refreshed: 30 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05136924.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing